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Abstract 
Review on t(6;8)(p21;q24), with data on clinics, and 
the genes involved. 
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Figure 1: t(6;8)(p21.1;q24.2), G-banding. Courtesy Hélène 
Bruyère. 
Clinics and pathology 
Disease 
Blastic plasmacytoid dendritic cell neoplasm 
(BPDCN) 
Phenotype/cell stem origin 
Disease derives from precursors of plasmacytoid 
dendritic cells. 
Epidemiology 
The t(6;8) has been found in a limited subset of 
BPDCN: Less than 10 cases reported to date. 
Preponderance of male cases (7/8 to date).  
Average age 65 years, in keeping with BPDCN's 
mean/median age of 61-67 (WHO Classification of 
Tumours of Hematopoietic and Lymphoid Tissues, 
2017). 
Clinics 
In general, BPDCN is an aggressive disease that 
most commonly involves the skin but can also 
infiltrate the bone marrow and peripheral blood as 
well as the lymph nodes.  
Seven out of eight cases of t(6;8) reported so far had 
bone marrow involvement based on bone marrow 
biopsy (Boddu et al., 2018; Momoi et al., 2002; 
Takiuchi et al., 2012; Nakamura et al., 2015; Fu et 
al., 2013; personal communication).  
One case reported by Leroux et al. in 2002 showed 
an extensive peripheral blood involvement with 95% 
circulating blasts.  
Although a bone marrow biopsy was not performed, 
the heavy involvement of peripheral blood, 
indicating bone marrow involvement, was sufficient 
to make the diagnosis. 
Cytogenetics 
Found with additional abnormalities in all cases, as 
the sole abnormality in the stemline in one case 
(Boddu et al., 2018), as a secondary abnormality in 
one case (Boddu et al., 2018), as part of a complex 
karyotype in 5/8 cases.  
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Table 1: Cases of BPDCN with t(6;8)(q21;q24). BM: bone marrow, LN: lymph node, PB: peripheral blood.  
 
 
Figure 2:  FISH image showing the presence of a normal (fused) MYC signal and separated 5'MYC signal from 3'MYC signal. 
 
 
Figure 3:  Image from immunohistochemistry with MYC antibody on bone marrow cells. 
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Of note, cytogenetic abnormalities are present in 
about two-thirds of BPDCN cases, involving 
chromosomes 5q34, 12p13, 13q13-21, 15q, and loss 
of chromosome 9 (WHO Classification of Tumours 
of hematopoietic and lymphoid tissues, 2017). 
Prognosis 
The prognosis of BPDCN is usually poor in adults 
(Bekkenk et al., 2004, Suzuki et al., 2005) and this 
appears to be true for cases with t(6;8). Two cases 
with this translocation failed to respond to treatment, 
the overall survival being 3 and 12 months 
respectively (Boddu et al., 2018). One patient 
relapsed three months after the initial diagnosis and 
treatment and received multiple lines of 
chemotherapy but eventually died because of septic 
shock nine months after the initial diagnosis (Momoi 
et al., 2002). The only female reported so far with 
t(6;8) received palliative chemotherapy and died two 
months after the initial diagnosis. Another patient 
responded to treatment and tumor cells in the 
peripheral blood disappeared in day 8; however, the 
patient died of septic shock on day 16 (Takiuchi et 
al., 2012). A 29-year-old male patient who was 
diagnosed with BPDCN with complex karyotype 
including t(6;8) received ALL-based chemotherapy 
achieved complete morphological remission by day 
24 of treatment and has been on sustained remission 
at least until this paper was written (personal 
communication). 
Cytogenetics 
The t(6;8)(p21.1;q24.2) is identified by conventional 
karyotyping.  
Note: Other translocations involving 8q24 have been 
reported in BPDCN: t(8;14)(q24;q32), 
t(X;8)(q24;q24), t(3;8)(p25;q24) (Boddu et al., 
2018; Nakamura et al., 2015) 
Genes involved and 
proteins 
MYC 
Location 
14q23.3 
DNA/RNA 
DNA/RNA: CMYC is composed of three exons 
spanning over 4 kb with the second and third exons 
encoding most MYC protein. 
SUPT3H 
Location 
6p21.1 
DNA/RNA 
DNA/RNA: SUPT3H is composed of 22 exons with 
a size of 570 kb. 
Protein 
399 amino acids and 44 kDa. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
The translocation has been shown to result in a split 
MYC signal when using a commercial MYC break-
apart FISH probe (Nakamura et al., 2015, Boddu et 
al., 2018, Fu et al., 2013). Involvement of the MYC 
gene has also be inferred from the positive MYC 
immunochemistry observed on bone marrow slides 
(Nakamura et al., 2015, Boddu et al., 2018). 
Molecular analysis of the 8q24 breakpoint showed 
that it occurred in the PVT1 gene on chromosome 8 
(Nakamura et al., 2015; Fu et al., 2013; Jardin et al., 
2009). PVT1 is located 149 kb telomeric to MYC. It 
is a long non-coding RNA located within the interval 
between the 5' MYC probe and 3'MYC commercial 
probes used to identify MYC rearrangements. Jardin 
et al. in 2009 found, in BPDCN, a 5.6-Mb interstitial 
deletion on 8q24 involving PVT1 bringing MYC 
oncogene adjacent to miR-30b/30c leading to 
possible up-regulation of these genes. 
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